Catheter-directed mechanical aspiration thrombectomy in a real-world pulmonary embolism population: a multicenter registry.
Catheter-directed mechanical aspiration thrombectomy
High-risk
Intermediate-high risk
Mortality
Pulmonary embolism
Safety
Journal
European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
received:
27
03
2023
revised:
08
06
2023
accepted:
14
06
2023
medline:
27
9
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
High- (HR) and intermediate-high risk (IHR) pulmonary embolisms (PEs) are related to high early mortality and long-term sequelae. We aimed to describe clinical outcomes and adverse events in IHR and HR pulmonary embolism (PE) treated with catheter-directed mechanical thrombectomy (CDMT) in a real-world population. This study is a multicenter, prospective registry enrolling 110 PE patients treated with CDMT between 2019 and 2022. The CDMT was performed using the 8F Indigo (Penumbra, Alameda, CA, USA) system bilaterally in pulmonary arteries (PAs). The primary safety endpoints included device or PE-related death during the 48-h after CDMT, procedure-related major bleeding, or other major adverse events. Secondary safety outcomes were all-cause mortality during hospitalization or the follow-up. The primary efficacy outcomes were the reduction of PA pressures and change in the right-to-left ventricular (RV/L) ratio assessed in the imaging 24-48 h after the CDMT.71.8% of patients had IHR PE and 28.2% HR PE. 11.8% of patients had a failure and 34.5% had contraindications to thrombolysis, and 2.7% had polytrauma. There was 0.9% intraprocedural death related to RV failure and 5.5% deaths within the first 48 h. CDMT was complicated by major bleeding in 1.8%, pulmonary artery injury in 1.8%, and ischaemic stroke in 0.9%. Immediate haemodynamic improvements included a 10.4 ± 7.8 mmHg (19.7%) drop in systolic PAP (P < 0.0001), a 6.1 ± 4.2 mmHg (18.8%) drop in mean PAP, and 0.48 ± 0.4 (36%) drop in RV/LV ratio (P < 0.0001). These observational findings suggest that CDMT may improve hemodynamics with an acceptable safety profile in patients with IHR and HR PE.
Identifiants
pubmed: 37319339
pii: 7199077
doi: 10.1093/ehjacc/zuad066
pmc: PMC10519874
doi:
Substances chimiques
Fibrinolytic Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-593Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
Catheter Cardiovasc Interv. 2022 Mar;99(4):1345-1355
pubmed: 35114059
Am J Med. 2015 Jul;128(7):747-59.e2
pubmed: 25680885
JACC Cardiovasc Interv. 2023 Mar 13;16(5):623-625
pubmed: 36922052
Pol Arch Intern Med. 2023 Mar 29;133(3):
pubmed: 36763072
Kardiol Pol. 2023;81(4):423-440
pubmed: 36951599
EuroIntervention. 2022 Oct 07;18(8):e623-e638
pubmed: 36112184
Eur Heart J Acute Cardiovasc Care. 2023 Apr 17;12(4):224-231
pubmed: 36738291
Kardiol Pol. 2022;80(9):956-957
pubmed: 35916487
J Thromb Thrombolysis. 2022 Feb;53(2):454-466
pubmed: 34463919
Eur Heart J Acute Cardiovasc Care. 2023 Feb 9;12(2):80-86
pubmed: 36580441
JACC Cardiovasc Interv. 2021 Feb 8;14(3):319-329
pubmed: 33454291
EuroIntervention. 2023 Feb 20;18(14):1201-1212
pubmed: 36349702
J Interv Cardiol. 2020 Aug 21;2020:4191079
pubmed: 32904502
Circulation. 2019 Nov 12;140(20):e774-e801
pubmed: 31585051
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619853037
pubmed: 31185730
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
JACC Cardiovasc Interv. 2019 May 13;12(9):859-869
pubmed: 31072507
JACC Cardiovasc Interv. 2015 Aug 24;8(10):1382-1392
pubmed: 26315743
AJR Am J Roentgenol. 2001 Jun;176(6):1415-20
pubmed: 11373204
Vasc Med. 2005 May;10(2):85-9
pubmed: 16013191
JACC Cardiovasc Interv. 2018 Jul 23;11(14):1401-1410
pubmed: 30025734
Kardiol Pol. 2020 Apr 24;78(4):300-310
pubmed: 32165606
Front Cardiovasc Med. 2022 Jun 16;9:861307
pubmed: 35783825
JACC Cardiovasc Interv. 2021 Jun 28;14(12):1364-1373
pubmed: 34167677
Kardiol Pol. 2021;79(12):1311-1319
pubmed: 34643260
Cardiol J. 2019;26(6):623-632
pubmed: 31970735
Cardiovasc Revasc Med. 2022 Jun;39:97-100
pubmed: 34706845
JACC Cardiovasc Interv. 2022 Dec 12;15(23):2427-2436
pubmed: 36121244
Pol Arch Intern Med. 2022 Oct 21;132(10):
pubmed: 35929841
Br Med J. 1971 Jun 19;2(5763):681-4
pubmed: 5556052
Eur Heart J Acute Cardiovasc Care. 2022 Sep 29;11(9):684-692
pubmed: 35830539
JAMA Cardiol. 2022 Dec 1;7(12):1189-1197
pubmed: 36260302
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242